Ossama Lashin, MD
Endocrinology, Diabetes & Metabolism · Lorain, OHNPI 1851507586
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 66.2% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $9,397, more than ten times the $664 reported in 2019.
Across 147 payments — averaging $144.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Siemens Medical Solutions USA, Inc.$5K
- Abbott$695
- AstraZeneca$375
- Lilly USA, LLC$299
- Tandem Diabetes Care, Inc.$209
- plus $811 from 10 others
Across 14 payments — averaging $8815.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$123K
What the payments were for
- Consulting fees$9,00042%
- Speaking & faculty fees$3,06014%
- Travel & lodging$3,16115%
- Food & beverage$6,01928%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 62 | $14,059 |
| Siemens Medical Solutions USA, Inc. | 1 | $4,800 |
| Abbott | 42 | $695 |
| AstraZeneca | 9 | $375 |
| Lilly USA, LLC | 12 | $299 |
| Tandem Diabetes Care, Inc. | 2 | $209 |
| Novo Nordisk | 6 | $170 |
| Ascendis Pharma Endocrinology Inc | 3 | $162 |
| Xeris Pharmaceuticals, Inc. | 1 | $97 |
| AbbVie | 1 | $91 |
| Bayer | 1 | $91 |
| Insulet Corporation | 1 | $87 |
| Corcept Therapeutics | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Antares Pharma, Inc. | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$10,925
- t:slim X2 Insulin Pump with Control-IQ$115
- MOUNJARO$114
- FARXIGA$112
- Yorvipath$107
How this compares
$21,248 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 99 | $8,602 |
| Levothyroxine Sodium | 378 | $4,361 |
| Armour ThyroidThyroid,pork | 18 | $1,491 |
| Liothyronine Sodium | 22 | $919 |
| Methimazole | 104 | $887 |
| Hydrocortisone | 14 | $799 |
| Testosterone Cypionate | 13 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid, Armour Thyroid | $91 | $10,093117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Lorain
- Anant JeetLorain$24K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.